COMP <GO>
SRPT vs SDGR // OPERATING MARGIN
Sarepta Therapeutics Inc. (NASDAQ) VS. Schrodinger Inc. (NASDAQ) • 15-METRIC TALLY: SRPT 3
— SDGR 6
▲ OPERATING MARGIN LEADER: SRPT
LAST: $18.32 (-1.61%) • MKT CAP: $1.97B
operating-margins
-37.50%
LAST: $26.19 (-3.50%) • MKT CAP: $2.03B
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRPT VS. SDGR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRPT | SDGR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 55.70% | +40.30 | SRPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.14% | 0.56% | -15.70 | SDGR | /fcf-yield <GO> |
| Operating Margin ACTIVE | -37.50% | -60.00% | +22.50 | SRPT | /operating-margins <GO> |
| Net Profit Margin | -38.30% | -40.40% | +2.10 | SRPT | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 23.30% | -19.00 | SDGR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 2.64 | -2.44 | SDGR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | SDGR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 51.8 | -1.10 | SDGR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.97B | $2.03B | -$63.4M | SDGR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRPT REV | SDGR REV | SRPT GROSS % | SDGR GROSS % | SRPT FCF | SDGR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.86B | $255.9M | 98.0% | 55.7% | -$307.5M | $12.5M |
| FY 2024 | $1.79B | $207.5M | — | 63.6% | -$342.7M | -$164.7M |
| FY 2023 | $1.14B | $216.7M | — | — | -$501.0M | -$136.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRPT // BETA —
SDGR // BETA —